The ARIQUELI study: Potentiation of quetiapine in bipolar I nonresponders with lithium versus aripiprazole

Trials

Volumn 14, Issue 1, 2013, Pages

  Missio, Giovani ^a   Moreno, Doris Hupfeld ^a   Fernandes, Fernando ^a   Bio, Danielle Soares ^a   Soeiro de Souza, Márcio Gehardt ^a   Rodrigues dos Santos, Domingos ^a   David, Denise Petresco ^a   Costa, Luis Felipe ^a   Demétrio, Frederico Navas ^a   Moreno, Ricardo Alberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Aripiprazole; Augmentation; Bipolar; Lithium; Potentiation; Refractory

Indexed keywords

ARIPIPRAZOLE; BIPERIDEN; LITHIUM; LORAZEPAM; QUETIAPINE; DIBENZOTHIAZEPINE DERIVATIVE; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; BIPOLAR I DISORDER; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DSM-IV-TR; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAXIMUM PERMISSIBLE DOSE; MIXED MANIA AND DEPRESSION; OUTCOME ASSESSMENT; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; BIPOLAR DISORDER; BRAZIL; CLINICAL PROTOCOL; DRUG COMBINATION; DRUG POTENTIATION; FEMALE; MALE; METHODOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAZIL; CLINICAL PROTOCOLS; DIBENZOTHIAZEPINES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879429715     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-190     Document Type: Article

References (38)

1. Goldberg JF. Optimizing treatment outcomes in bipolar disorder under ordinary conditions. J Clin Psychiatry 2008, 69(Suppl 3):11-19.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Washington DC: American Psychiatric Association, Fourth, American Psychiatric Association.
3. Beyer JL. An evidence-based medicine strategy for achieving remission in bipolar disorder. J Clin Psychiatry 2008, 69(Suppl 3):31-37.
4. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006, 163(Suppl 2):217-224.
5. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 2002, 63(Suppl 10):5-12.
6. Young AH, MCElroy S, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M, EMBOLDEN I (Trial 001) Investigators A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010, 71(Suppl 2):150-162. EMBOLDEN I (Trial 001) Investigators.
7. Zhornitsky S, Potvin S, Moteshafi H, Dubreucg S, Rompré PP, Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol 2011, 26(Suppl 4):183-192.
8. Gajwani P, Muzina DJ, Kemp DE, Gao K, Calabrese JR. Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies. Neuropsychiatry Dis Treat 2007, 3(Suppl 6):847-853.
9. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomized, placebo-controlled studies. Curr Med Res Opin 2005, 21(Suppl 6):923-934.
10. Li H, Ma C, Wang G, Zhu X, Peng M, Gu N. Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: a randomized and double-blind study. Curr Med Res Opin 2008, 24(Suppl 1):1-10.
11. Brahm NC, Gutierres SL, Carnahan RM. Quetiapine for acute mania in bipolar disorder. Am J Health Syst Pharm 2007, 64(Suppl 10):1045-1053.
12. Nivoli AM, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, Gonzáles-Pinto A, Fountoulakis KN, Vieta E. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011, 129(Suppl 1-3):14-26.
13. Tamayo JM, Zarate CA, Vieta E, Vásques G, Tohen M. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2010, 13(Suppl 6):813-832. 3005373, 20128953.
14. Gershon S, Chengappa KN, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord 2009, 11(Suppl 2):34-44.
15. Moreno RA, Moreno DH, Soares MB, Ratzke R. Anticonvulsivants and antipsychotics in the treatment of bipolar disorder. Rev Bras Psiquiatr 2004, 3:37-43.
16. Taveira ACA, Moreno RA. Brazilian psychiatry attitude toward lithium and others mood stabilizers use in the bipolar disorder. Master's degree dissertation 2007, School of Medicine, University of São Paulo.
17. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Milman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust phamarcology. Neuropsychopharmacology 2003, 28:1400-1411. 10.1038/sj.npp.1300203, 12784105.
18. Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010, 26:1458-1496.
19. Dunn RT, Stan VA, Chriki LS, Filkowski MM, Ghaemi SN. A prospective, open label study of aripiprazole mono and adjunctive treatment in acute bipolar depression. J Affect Disord 2008, 110:70-74. 10.1016/j.jad.2008.01.004, 18272230.
20. Kemp DE, Gilmer WS, Fleck J, Strauss JL, Dago PL, Karaffa M. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychoparmacol Biol Psychiatry 2007, 31:574-577.
21. Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006, 18:169-172. 10.1080/10401230600801176, 16923655.
22. McElroy SL, Suppes T, Frye MA, Altshuler LL, Stanford K, Martens B, Leverich GS, Post RM, Keck PE. Open-Label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord 2007, 101:275-281. 10.1016/j.jad.2006.11.025, 17229469.
23. Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH, CN138-135 Study Group Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo-and lithium-controlled study. J Affect Disord 2009, 112:36-49. 10.1016/j.jad.2008.05.014, 18835043, CN138-135 Study Group.
24. Yatham LN. A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. J Affect Disord 2011, 128(Suppl 1):S21-S28.
25. Sokolski KN. Adjunctive aripiprazole in bipolar I depression. Ann Pharmacother 2007, 41:35-40.
26. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMC Med 2010, 8(Suppl 1):18. 2860339, 20334633.
27. Cohen J. Statistical power analysis for the behavior science 1988, Hillsdale, NJ: Erlbaum, 2.
28. Bauer M, Alda M, Priller J, Young LT, International Group for the Study of Lithium Treated Patients Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 2003, 36(Suppl 3):S250-S254. International Group for the Study of Lithium Treated Patients.
29. Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KR, Grunze H, Mitchell PB, Kanba S, Berk M. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009, 11(Suppl 5):453-473.
30. Hirschfeld RMA, Calabrese JR, Frye MA, Lavori PW, Sachs G, Tase M, Wagner KD. Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening. Psychopharmacol Bull 2007, 40(Suppl 3):7-14.
31. Vieta PE, Torrent FC, Martínez-Arán A, Colom VF, Reinares GM, Benabarre HA, Comes FM, Goikolea AJM. A user-friendly scale for the short and long term outcome of bipolar disorder: the CGI-BP-M. Actas Esp Psiquiatr 2002, 30(Suppl 5):301-304.
32. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987, 334(Suppl 1):100.
33. WHO What quality of life? World Health Organization qualitiy of life assessment. World Health Forum 1996, 17(Suppl 4):354-356. WHO.
34. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976, 33:1111-1115. 10.1001/archpsyc.1976.01770090101010, 962494.
35. Fleck MPA. O instrumento de avaliação de qualidade de vida da Organização Mundial da Saúde (WHOQOL-100): características e perspectivas. Ciênc Saúde Coletiva 2000, 5(Suppl 1):33-38.
36. Gorenstein C, Andrade L, Moreno RA, Bernik MA, Nicastri S, Cordás TA, Camargo AP. Escala de auto avaliação de adequação social: validação da versão em língua portuguesa. Escalas de avaliação clínica em psiquiatria e psicofarmacologia 2000, 401-414. São Paulo: Lemos, Gorenstein C, Andrade LHSG, Zuardi AW.
37. Spreen O, Strauss E. A Compendium of neuropsychological tests 1998, Oxford: Oxford University Press.
38. Wechsler D. Wechsler Abbreviated Scale of Intelligence 1999, New York: Psychological Corporation.